INTRODUCTION
The insulin-like growth factors IGF-1 and IGF-2, first isolated from human serum (Rinderknecht & Humbel, 1976) , have been shown to stimulate a pleiotrophic growth response affecting rates of protein synthesis, protein degradation, DNA synthesis and the transport of substrates (Van Wyk, 1984; Ballard et al., 1986) . Both IGF-1 and IGF-2 have been shown to promote the growth of hypophysectomized as well as normal animals (Schoenle et al., 1982 (Schoenle et al., , 1985 Hizuka et al., 1986) . The insulin-like growth factors have been isolated in a purified state from only a few species, including human, rat and the cow (Rinderknecht & Humbel, 1978a,b; Marquardt et al., 1981; Rubin et al., 1982; Francis et al., 1986; Honegger & Humbel, 1986) . Purification from human and bovine serum (Zumstein & Humbel, 1985; Blum et al., 1986; Honegger & Humbel, 1986) and bovine colostrum has indicated that a family of minor forms may also exist in vivo.
Assessment of the importance of variant forms of IGF requires isolation of sufficient quantities for structural and biological studies. Previously we reported the partial sequence of a truncated form of bovine IGF-1 that copurified with apparently authentic IGF-1 . Sara et al. (1986) have also reported a truncated IGF-1 isolated from human brain that was only partly characterized owing to the small quantities obtained. We now report an improved purification procedure from bovine colostrum that has provided sufficient yields to complete the amino acid sequencing of this modified IGF-1. IGF-1 and IGF-2 purified at the same time were also sequenced. The effects of IGF-1, truncated IGF-1 and IGF-2 on protein synthesis, protein degradation and DNA synthesis in L6 myoblasts were compared to determine whether differences in biological potency occur between the different forms.
EXPERIMENTAL Materials
Colostrum was collected before suckling on the day-of parturition and supplied by Mr. B. Euwing, Mylor, South Australia, Australia. The colostrum was stored at -20 'C. [4,5-3H] Leucine (specific radioactivity 40-60 Ci/mmol), thymidine (50 Ci/mmol), iodo-[2-14C]acetic acid (56 mCi/mmol) and carrier-free Na125I were purchased from Amersham International, Amersham, Bucks., U.K. Foetal bovine serum was obtained from Flow Laboratories, North Ryde, N.S.W., Australia. Sources for media, antibiotics and the L6 myoblasts have been given previously (Ballard, 1982) . Bovine serum albumin (radioimmunoassay grade) was purchased from Sigma Chemical Co., St. Louis, MO, U.S.A., heptafluorobutyric acid (sequencing grade) was from Beckman Instruments, Palo Alto, CA, U.S.A., trifluoroacetic acid (synthesis grade) was from Merck, Darmstadt, Germany, and 1,1,2-trichloro-1,2,2-trifluoroethane (A.R. grade), Australia, and Brownlee Laboratories, Santa Clara, CA., U.S.A. Endoproteinase Glu-C was purchased from Boehringer Mannheim, North Ryde, N.S.W., Australia. Other materials used in the purification were obtained from suppliers listed previously . Measurement of IGF Bovine IGF-1, -3N: IGF-1 and IGF-2 were each iodinated to a specific radioactivity of approx. 100-150 Ci/g by using the chloramine-T method as described by Van Obberghen-Schilling & Pouyssegur (1983) . Separation of the labelled peptides from iodide that had not reacted and aggregated products was accomplished on a Sephadex G-100 column equilibrated with 50 mmsodium phosphate buffer, pH 6.5, containing 0.2 % (w/v) bovine serum albumin.
The bioassay for total IGF activity based on the stimulation of protein-synthesis activity in confluent L6 rat myoblasts has been described previously . Briefly, this involved measuring the incorporation of [3H]leucine into cell protein during a 17 h incubation. The activity is expressed as percentage stimulation above a buffer control.
Measurement of IGF-1 by radioimmunoassay was carried out as described previously except that the monoclonal antibody used previously was replaced by a rabbit antiserum to IGF-1 kindly provided by Dr. L. Underwood and Dr. J. J. Van Wyk through the National Hormone and Pituitary Program of the National Institute of Diabetes, Digestive and Kidney Disease. Under the conditions of the assay 50 % displacement of the tracer was achieved with the addition of 50 pg of IGF-1, 200 pg of -3N:IGF-1 and 2 ng of IGF-2 per tube.
Measurement of IGF-2 by competitive binding to L6 rat myoblasts was carried out essentially as described previously , except that the radioactive ligand used was '25I-labelled bovine IGF-2. Under the conditions employed 25 % displacement of bound tracer occurred with the addition of 1,ug of IGF-1, 250 ng of -3N: IGF-1 and 4 ng of IGF-2 per well. Halfmaximum competition was achieved by the addition of 20 ng of IGF-2.
The protein content ofIGF preparations was measured by their absorbance at 280 nm and quantified by using crystalline pig insulin as standard.
Purification of IGF
The purification was performed by following the method of Francis et al. (1986) as outlined below. Detailed descriptions are presented for steps that have been changed substantially.
Acid extraction. Approx. 4 litres of colostrum were centrifuged at 20000 g for 20 min at 5 'C. The infranatant (3.9 litres) was stirred with 0.33 vol. of 1,1,2-trichloro-1,2,2-trifluoroethane for 15 min at 5 'C before centrifugation at 3500 g for 15 min. The lipid-free supernatant (3.4 litres) was adjusted to pH 2.5 with acetic acid while being stirred vigorously before an equal volume of 1 Macetic acid containing 250 mM-NaCl was added, and stirring was continued overnight at 5 'C. Acetonitrile was added at a final concentration of 10 % (v/v) and the mixture stirred for a further 15 min, whereupon centrifugation at 20000 g for 20 min yielded a clear extract (4.5 litres). The large pellet contained more than 90 % of the protein but little protein-synthesis-stimulating activity.
SP-Sephadex cation-exchange chromatography. This step was carried out as described previously ).
Concentration on silica C.8. The eluate from SPSephadex chromatography was adjusted to 0.1 % (v/v) trifluoroacetic acid and 10% (v/v) acetonitrile and the pH to 2.1 with 6 M-HCI. This mixture was stirred overnight, and the precipitate that formed was removed by centrifugation at 20000 g for 20 min. The supernatant was pumped at a flow rate of 15 ml/min on to a 2.2 cmdiameter glass column containing 12 g of Amicon silica C18 chromatography medium equilibrated with 10 % (v/v) acetonitrile in 0.1 % (v/v) trifluoroacetic acid. The column was washed with the equilibration solution, and the IGFs were eluted with 100 ml of 50 % (v/v) acetonitrile in 0.1 % (v/v) trifluoroacetic acid at a flow rate of 2 ml/min.
Fractogel TSK gel-permeation h.p.l.c. The eluate was freeze-dried and redissolved in 60 ml of 1 M-acetic acid. The clear solution was chromatographed at a flow rate of 2 ml/min on a 5 cm diam. x 100 cm column of Fractogel TSK HW-55 (S) previously equilibrated with 1 M-acetic acid.
First reverse-phase h.p.l.c. Following the acid gelpermeation h.p.l.c., IGF-containing fractions that were eluted between 0.9-and 1.0 column volumes were adjusted to 0.13% (v/v) heptafluorobutyric acid and applied to an Amicon silica C18 h.p.l.c. column Second reverse-phase h.p.l.c. This step was carried out as described by Francis et al. (1986) , whereon three peaks of protein-synthesis-stimulating activity were eluted by a two-step linear gradient to 44 % (v/v) acetonitrile in 0.1 % (v/v) trifluoroacetic acid. The largest of these peaks, containing more than 80 % of the bioactivity, was selected for further purification.
Mono S cation-exchange chromatography. The pooled fractions were pumped directly on to a Pharmacia Mono S HR 5/5 column equilibrated with 10 mM-ammonium acetate buffer, pH 4.8, in 10% (v/v) acetonitrile. Protein, monitored by the absorbance at 280 nm, was eluted at a flow rate of 1 ml/min with a gradient of 10 mm-to 1 Mammonium acetate buffer, pH 4.8, in 10 % (v/v) acetonitrile, and fractions were assayed in the protein-synthesis bioassay and IGF-2 radio-receptor assay (Fig. 1) . Two pools were taken for further purification; the first (pool A) contained the IGF-1 radioimmunoassay and proteinsynthesis-stimulating activity and the second (pool B) contained all the IGF-2 radio-receptor assay activity. Fourth reverse-phase h.p.l.c. After adjustment of the pools to 0.13 % (v/v) heptafluorobutyric acid, they were injected separately on to the same column as above but equilibrated with 10% (v/v) propan-1-ol. All solvents for this step contained 0.13% (v/v) heptafluorobutyric acid. The propan-1-ol concentration was stepped up to 27.5% (v/v) and the IGFs were eluted with a linear gradient to 41.5% (v/v) over 140 min at a flow rate of 1 ml/min. Fractions were assayed in the protein synthesis bioassay and IGF-2 radio-receptor assay ( Previously we reported the purification of bovine IGF-1 from colostrum and the partial amino acid sequence of this peptide . Further investigation of the biological and receptor-binding properties of that material was complicated by unreliable yields and variable purity. The method described in the present paper overcomes these problems.
It has become apparent from our work and others (Hossenlopp et al., 1986; Rosenfeld et al., 1987) that it is extremely difficult to remove all traces of IGF-2 from preparations of IGF-1. Thus Rosenfeld et al. (1987) argued that the 5-20 % cross-reactivity of IGF-1 for the IGF-2 receptor reported previously was probably due to a small but significant IGF-2 contamination. This conclusion was based on the finding that synthetic and recombinant-derived IGF-1 demonstrated an affinity for IGF-2 receptors only 1-10 % of that exhibited by IGF-1 preparations purified from natural sources.
In the L6 myoblast IGF-2 radio-receptor assay used here the level of cross-reaction shown by purified IGF-1 was less than 0.5 %. Moreover in a number of studies with other cell lines we have found a similar degree of competition of IGF-1 for IGF-2 binding (results not shown). Thus our preparations ofIGF-1 behave similarly to recombinant and synthetic IGF-1 in this regard and appear to be free of IGF-2 contamination. Inclusion of the Mono S cation-exchange step (Fig. 1) facilitated the separation of IGF-1 from IGF-2, the resultant pool of IGF-1 being eluted well before the appearance of any activity detectable by the IGF-2 radio-receptor assay. Furthermore, IGF-1, assayed by both the proteinsynthesis bioassay and the IGF-1 radio-receptor assay, was eluted earlier than IGF-2 under the conditions of the third and fourth h.p.l.c. steps.
The final h.p.l.c. step (Fig. 2b) clearly resolved the protein-synthesis-stimulating activity into two separate peaks. The first peak eluted possessed an N-terminal sequence identical with that of human IGF-1, but the second peak of bioactivity contained a truncated form of IGF-1 that lacked the N-terminal tripeptide Gly-ProGlu. The complete characterization of these peptides supports our earlier finding that the protein-synthesisstimulating activity in bovine colostrum was due to the presence of two forms of IGF-1 . The purity of IGF-1 and -3N: IGF-1 was established by amino acid sequence analysis of approx. 1 nmol of each peptide. Under the conditions employed the presence of a trace contaminant contributing between 2-5 % of the phenylthiohydantoin amino acid yield in each of the first few cycles would have been detected. Also, the presence of an IGF-2 sequence was never detected during such Nterminal sequence analysis. The purification of IGF-2 to homogeneity was also achieved in the final h.p.l.c. step with the recovery of approx. 20 ,ug of material from each purification (Fig.  2a) . Several cycles of N-terminal sequence analysis were performed on batches of this material to establish purity as above for the other IGF. On no occasion was the presence of IGF-1 ever detected (see Table 1 below). This situation is a consequence of the last three steps of the purification procedure all resolving IGF-1 from IGF-2.
The amount of IGF-1 in the starting colostrum was estimated from analysis of the defatted acetic acid/ acetonitrile extract. IGF-1 was separated from binding proteins by acid gel-permeation h.p.l.c. essentially as (------) and pooled for sequencing on the basis of their A215 ( ) and radioactivity (@).
described by Scott et al. (1985) and measured by radioimmunoassay. The amount found in the initial extract was 2 mg, from which 100 ,Cg of IGF-1 and 50 ,ug of -3N: IGF-1 were purified, thus representing an overall yield of approx. 5-10 %. Sequence analysis The sequence of bovine serum IGF-1 has been reported to be identical with that of human IGF-1 (Honegger & Humbel, 1986) . We had previously obtained data from comparative binding studies of bovine, human and rat IGFs to membrane receptors and to antibodies against human IGF-1 suggesting that differences existed between bovine IGF-1 and human IGF-1 . These results, together with the reported heterogeneity of IGF-l in human serum (Blum et al., 1986) , raised the possibility that the IGF-1 purified from bovine colostrum (Fig. 3a) . The remainder of the sequence was determined from the analysis of peptides generated by digestion with endoproteinase Glu-C and separated on micro-bore h.p.l.c. (Fig. 3c) . The peak G5 was selected for sequencing, as its higher specific radioactivity indicated that it was the predicted 12-amino-acid-residue peptide containing three 'IC-labelled cysteine residues. Correspondingly the low specific radioactivity of peak G6 suggested it was the 36-aminoacid-residue peptide containing only one labelled cysteine residue. Under the conditions employed endoproteinase Glu-C cleaved almost exclusively at the C-terminal side of glutamic acid residues. However, in the case of the sequence Asp-Glu at positions 45 and 46 it cut equally at the C-terminal side of both aspartic acid and glutamic acid to give the resulting peaks, G5 and G6, both of which on sequencing were found to contain two variants (Fig. 3c) . The IGF-1 sequence was completed by the analysis of peak G4, which consisted of the Cterminal 12-amino-acid-residue peptide beginning with Vol. 251 was eluted coincident with the largest peak ofabsorbance. This and the other minor peaks were not characterized further. The resultant complete sequence of bovine IGF-1 from colostrum ( Fig. 3b) is identical with that reported for IGF-1 purified from bovine serum (Honegger & Humbel, 1986) . The mouse is the only other species for which the complete sequence of IGF-l is known. The amino acid sequence for mouse IGF-1 was deduced from the cDNA sequence and is different from the human sequence at only three positions (Bell et al., 1986) . Clearly the amino acid structure of IGF-I is highly conserved.
The comnplete sequence ofthe N-terminal des-tripeptide form of bovine IGF-I was determined by employing the same techniques as described above for IGF-I (Fig. 4) . A very similar endoproteinase Glu-C digest pattern was seen and the h.p.l.c. peaks were chosen for sequencing accordingly (Fig. 4c) Rinderknecht & Humbel (1978a) , Rubin et al. (1982) and Bell et al. (1986) respectively. Sequences of human and rat IGF-2 are from Rinderknecht & Humbel (1978b) and Marquardt et al. (1981) respectively. Residues different from the bovine sequence are indicated by an asterisk and unknown residues are shown as a dash.
identical with those obtained with IGF-1 (compare Fig.  3c and Fig. 4c ) and no differences from IGF-1 were found other than the loss of the N-terminal tripeptide (Fig. 4b) . A truncated form of IGF-1 has also been reported in human foetal and adult brain and, although in both cases only partial sequences were reported, it seems likely that the truncated form is the same as reported here for the bovine peptide. N-Terminal sequence analysis of bovine IGF-2 up to position 45 revealed three differences from that of human IGF-2 (Fig. Sa, Table 1 and Fig. 6 ). These changes at residues 32, 35, and 36 involved substitution of serine, valine and asparagine for alanine, valine and serine respectively. The remaining sequence of IGF-2 was obtained from analysis of the peptides GI, G2 and G3 generated by endoproteinase Glu-C digestion of ["CIcarboxymethylated growth factor ( Fig. 5 and Table 1 ). Peptide GI consisted of the C-terminal decapeptide. G2 represented the next peptide from the C-terminus, but was actually a mixture of two peptides produced as a consequence of cleavage at consecutive glutamic acid residues 44 and 45 with equal frequency. This situation was also observed with IGF-1 and -3N:IGF-11, where the respective amino acids are aspartic acid and glutamic acid (see above). Sequencing of peptide G3, which probably represented undigested [14C]carboxymethylated growth factor, allowed confirmation of the two remaining cysteine residues at positions 9 and 21.
The complete IGF-2 sequence differed from human IGF-2 by substitution at residues 32, 35 and 36 (Fig. 6 ) and from the previously reported bovine serum IGF-2 (Honegger & Humbel, 1986) by the replacement of isoleucine for serine at position 35. Our result was substantiated on two occasions (Table 1) , and careful examination of the amino acid analysis data reported by Honegger & Humbel (1986) supports the presence of an extra isoleucine residue.
If in the cow only one IGF-1 gene exists, as is the case in the human (Brissenden et al., 1984) , generation of the truncated IGF-1 is most likely the result of posttranslational modification. Alternatively it could-arise from alternative splicing of the bovine IGF-I mRNA, but this appears to be unlikely in the human owing to the absence of an intron-exon hinge region near the Nterminus of IGF-1 (Rotwein et al., 1986 ). Isolation of apparently the same truncated form of IGF-1 from human brain Carlsson-Skwirut et al., 1986) and bovine colostrum by different procedures suggests it arises by post-translational modification in vivo. More recently Carlsson-Skwirut et al. (1987) have reported the presence of truncated IGF-1 in human foetal serum and suggested that it is the major foetal form of IGF-1. Unfortunately, this was not verified by N-terminal sequencing. In order to resolve the question about the origin of the truncated IGF-1 we have processed 2 litres of bovine foetal serum by the purification procedure reported here and, although we recovered significant quantities of IGF-1 and IGF-2 in pure form, there was no indication of the presence of -3N: IGF-1 (results not shown). Hence -3N: IGF-1 does not appear to be generated during the isolation procedure, at least from serum.
Biological studies
The potencies of the isolated IGF to stimulate a coordinate growth response in L6 rat myoblasts were compared. At the highest concentrations tested all three peptides inhibited the basal rate of protein degradation by a maximum of 40 % over the 4 h measurement period (Fig. 7c) . The decreasing order of potency with the concentrations (ng/ml) required to give a half-maximal response in parentheses was:
-3N:IGF-1 (0.2) > IGF-1 (1.6) > IGF-2 (8.4) The IGF preparations all stimulated protein synthesis in L6 myoblasts to the same extent (Fig. 7b) residue peptide (B-domain) of IGF-1 led to diminished activity . These results agree with the report by De Vroede et al. (1986) that a chemically synthesized hybrid containing the A-chain of insulin and the B-domain of IGF-I had diminished mitogenic activity comrpared with insulin. Thus it appears that the A-and D-domains of IGF-1 are important for mitogenic activity whereas the N-terminal B-domain is relatively less so. Also, Blundell et al. (1983) have proposed from computer graphic modelling that the N-terminal residues of IGF-1 are not involved in receptor binding. However, these results and predictions are at variance with our observations that loss of the tripeptide Gly-Pro-Glu from the Bdomain markedly increases the biological activity of IGF-1. More extensive research is required to clarify the region of the IGF-1 molecule required for biological activity. A likely explanation of our observations is that interaction with the type 1 IGF-1 receptor is altered in some way by removal of the N-terminal tripeptide, the end result being an enhancement of the biological potency.
In conclusion it appears that a modified IGF-1 lacking the N-terminal tripeptide Gly-Pro-Glu is present in bovine colostrum and possesses enhanced biological activity compared with IGF-1. Although we could not identify this growth factor in bovine foetal serum, others have established the presence of a truncated IGF-1 in human brain . If, as appears likely, it does not arise during the isolation procedure, we must conclude that similar proteolytic processing mechanisms operate in the mammary gland and in the central nervous system to produce the novel peptide.
